We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finalizes Guidance on Charging for Investigational Drugs, Takes Other Actions
FDA Finalizes Guidance on Charging for Investigational Drugs, Takes Other Actions
The FDA has issued final guidance on charging for investigational new drugs in clinical trials, offering a minor update to its recommendations. In addition, the agency has published new draft and revised product-specific guidances and extended the comment period for its guidance on trial master protocols.